Evidence map›Paper›PMID 36928033›Full record

ArticlePLoS biology2023

Targeting NAD+ regeneration enhances antibiotic susceptibility of Streptococcus pneumoniae during invasive disease.

Hansol Im, Madison L Pearson, Eriel Martinez, Kyle H Cichos, Xiuhong Song, Katherine L Kruckow, Rachel M Andrews, Elie S Ghanem, Carlos J Orihuela

Open access · goldFull text read
In one paragraph

Article in PLoS biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. mBio · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hansol ImDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-0629-7461
Madison L PearsonDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Eriel MartinezDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Kyle H CichosDepartment of Orthopaedic Surgery Arthroplasty Section, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Xiuhong SongDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Katherine L KruckowDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Rachel M AndrewsDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Elie S GhanemDepartment of Orthopaedic Surgery Arthroplasty Section, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Carlos J OrihuelaDepartment of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-8542-4069
University of Alabama at Birmingham · US

Funding

Cardiac microlesion formation during invasive pneumococcal diseaseR01AI114800 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Carlos J Orihuela, Herve S TETTELIN · 2015 to 2026
$5.1M
Molecular mechanisms underlying organ penetration in disseminated pneumococcal infectionR01AI172796 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Carlos J Orihuela, Min Xie · 2023 to 2026
$2.6M
PspA binds necroptotic cells to cause disease and transmitR01AI156898 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ORIHUELA, CARLOS J · 2020 to 2024
$2.0M
Basic and Translational Science in Heart FailureT32HL129948 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YOUNG, MARTIN E · 2017 to 2021
$1.4M
Capsule protects intracellular pneumococci during vascular endothelial cell translocationR21AI148368 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ORIHUELA, CARLOS J · 2020 to 2021
$408k
NHLBI NIH HHS T32 HL129948NIAID NIH HHS R01 AI114800NIAID NIH HHS R01 AI156898NIAID NIH HHS R01 AI172796NIAID NIH HHS R21 AI148368
6 · The paper itself

Abstract

Anaerobic bacteria are responsible for half of all pulmonary infections. One such pathogen is Streptococcus pneumoniae (Spn), a leading cause of community-acquired pneumonia, bacteremia/sepsis, and meningitis. Using a panel of isogenic mutants deficient in lactate, acetyl-CoA, and ethanol fermentation, as well as pharmacological inhibition, we observed that NAD(H) redox balance during fermentation was vital for Spn energy generation, capsule production, and in vivo fitness. Redox balance disruption in fermentation pathway-specific fashion substantially enhanced susceptibility to killing in antimicrobial class-specific manner. Blocking of alcohol dehydrogenase activity with 4-methylpyrazole (fomepizole), an FDA-approved drug used as an antidote for toxic alcohol ingestion, enhanced susceptibility of multidrug-resistant Spn to erythromycin and reduced bacterial burden in the lungs of mice with pneumonia and prevented the development of invasive disease. Our results indicate fermentation enzymes are de novo targets for antibiotic development and a novel strategy to combat multidrug-resistant pathogens.

Indexed as

NADStreptococcus pneumoniaeAnimalsAnti-Bacterial AgentsErythromycinLungMiceAnti-Bacterial AgentsErythromycinNAD

Identifiers

PMID36928033
PMCPMC10019625
OpenAlexW4327568766

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read72
identifiers read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.